Sunshine Biopharma
SBFM
1 hedge funds and large institutions have $800K invested in Sunshine Biopharma in 2022 Q2 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, reducing their positions, and 3 closing their positions.
4.44% less ownership
Funds ownership: 8.9% → 4.46% (-4.4%)
67% less funds holding
Funds holding: 3 → 1 (-2)
67% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 3
71% less capital inflows, than outflows
Capital inflows: $977K | Capital outflows: $3.41M
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bridgeway Capital Management
Houston,
Texas
|
+$977K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Armistice Capital
New York
|
-$1.56M |
| 2 |
Empery Asset Management
New York
|
-$1.1M |
| 3 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
-$720K |
| 4 |
Jane Street
New York
|
-$31K |
SBFM Hedge Fund Activity: Q2 2022 in Review
1 of the 5,963 institutional investors tracked by Wall St. Rank reported a position in Sunshine Biopharma (SBFM) for Q2 2022, worth a combined $800K — down 77% from $3.55M a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of SBFM and 1 opened new positions — a net loss of 2 holders — while 0 trimmed existing stakes and 0 added.
The largest buyer was Bridgeway Capital Management, opening a new position worth an estimated $977K. The largest seller was Armistice Capital, exiting entirely with an estimated $1.56M sold.
- 1 institutional investor held Sunshine Biopharma (SBFM) as of Q2 2022, down from 3 in Q1 2022.
- Funds reported $800K of Sunshine Biopharma stock for Q2 2022, down 77% quarter-over-quarter.
- 1 fund opened new Sunshine Biopharma positions in Q2 2022 and 3 closed out, a net change of -2 holders.
- The largest Sunshine Biopharma buyer in Q2 2022 was Bridgeway Capital Management, an estimated $977K added.
- The largest Sunshine Biopharma seller in Q2 2022 was Armistice Capital, an estimated $1.56M sold.
Based on aggregated 13F filings for Q2 2022.